LLY ▼ -0.4% - Eli Lilly and Company $LLY - U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer Eli Lilly received FDA approval for Inluriyo combined with Verzenio to treat a specific subset of advanced breast cancer patients with ESR1 mutations, expanding the therapeutic options for this patient population. Despite the positive regulatory milestone, LLY shares declined 0.4% today, suggesting investors may have already priced in the approval or were looking for broader label indications. 18-SEP-2026 01:55 PM ET